NCT01261767 - First Human Dose Study of Anti-IL-20 in Psoriasis: A Study of Safety, Tolerability and Early Signals of Biologic and Clinical Effects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions

InflammationPsoriasis

Interventions

DRUG

anti-IL-20

Anti-IL-20 in 100mg/vial for subcutaneous (under the skin) injection

DRUG

placebo

Placebo for subcutaneous (under the skin) injection

Trial Locations (16)

10010

Novo Nordisk Investigational Site, New York

10029

Novo Nordisk Investigational Site, New York

21225

Novo Nordisk Investigational Site, Baltimore

27157

Novo Nordisk Investigational Site, Winston-Salem

35294

Novo Nordisk Investigational Site, Birmingham

60077

Novo Nordisk Investigational Site, Skokie

75246

Novo Nordisk Investigational Site, Dallas

90036

Novo Nordisk Investigational Site, Los Angeles

46256-4697

Novo Nordisk Investigational Site, Indianapolis

02111-1526

Novo Nordisk Investigational Site, Boston

63117-1206

Novo Nordisk Investigational Site, St Louis

08903

Novo Nordisk Investigational Site, New Brunswick

97210-5102

Novo Nordisk Investigational Site, Portland

97239-4501

Novo Nordisk Investigational Site, Portland

84132-0002

Novo Nordisk Investigational Site, Salt Lake City

23507-1970

Novo Nordisk Investigational Site, Norfolk